At Carmot, we aim to discover, develop and bring disease-modifying therapies to people living with metabolic diseases, including obesity and diabetes.
Modulating core energy homeostatic pathways is critical to addressing this disease burden. Our clinical pipeline targets two main incretins, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP), both of which play significant roles in energy homeostasis.